{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T15:52:20Z","timestamp":1757778740992},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[1986,1,1]],"date-time":"1986-01-01T00:00:00Z","timestamp":504921600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[1986]]},"DOI":"10.1007\/bf00542414","type":"journal-article","created":{"date-parts":[[2004,11,19]],"date-time":"2004-11-19T04:41:33Z","timestamp":1100839293000},"page":"553-557","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of once daily endralazine in hypertension"],"prefix":"10.1007","volume":"30","author":[{"given":"R.","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. D.","family":"Spence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. G.","family":"Carruthers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","first-page":"95","volume":"7","author":"MG Baird","year":"1984","unstructured":"Baird MG, Bentley-Taylor MM, Carruthers SG, et al. (1984) A study of efficacy, tolerance and compliance of once-daily versus twice-daily metoprolol (Betaloc) in hypertension. Clin Invest Med 7: 95?102","journal-title":"Clin Invest Med"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF00610045","volume":"24","author":"WAJL Bogers","year":"1983","unstructured":"Bogers WAJL, Meems L (1983) Endralazine, a new peripheral vasodilator. Evaluation of safety and efficacy over a 3-year period. Eur J Clin Pharmacol 24: 301?305","journal-title":"Eur J Clin Pharmacol"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1056\/NEJM196703022760902","volume":"276","author":"JJ Condemi","year":"1967","unstructured":"Condemi JJ, Moore-Jones D, Vaughan JH, Perry HM (1967) Antinuclear antibodies following hydralazine toxicity. N Eng J Med 276: 486?491","journal-title":"N Eng J Med"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/bmj.290.6469.675","volume":"290","author":"M Doherty","year":"1985","unstructured":"Doherty M, Maddison PJ, Grey RHB (1985) Hydralazine induced lupus syndrome with eye disease. Br Med J 290: 675","journal-title":"Br Med J"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(83)90727-4","volume":"2","author":"MDC Donaldson","year":"1983","unstructured":"Donaldson MDC, Chambers TL (1983) Endralazine in treatment of hypertension in children with renal disease. Lancet 2: 635","journal-title":"Lancet"},{"key":"CR6","first-page":"42","volume":"30","author":"I Dvorak","year":"1984","unstructured":"Dvorak I, Dvorak M, Blaha M, Kubesova H, Havlat F, Nemcova H (1984) Zkusenosti s endralazinem v lecbe esencialni hypertenze. Vnitrni lekarstvi 30: 42?47","journal-title":"Vnitrni lekarstvi"},{"issue":"8","key":"CR7","first-page":"1409","volume":"A4","author":"HL Elliott","year":"1982","unstructured":"Elliott HL, McLean K, Sumner DJ, Donnelly RJ, Reid JL (1982) Clinical evaluation of endralazine (BQ 22708), a new vasodilator, in essential hypertension. Clin Exper Hypertens A4 [8]: 1409?1418","journal-title":"Clin Exper Hypertens"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2125.1981.tb01131.x","volume":"11","author":"V Facchini","year":"1981","unstructured":"Facchini V, Timbrell JA (1981) Further evidence for acetylator phenotype difference in the metabolism of hydralazine in man. Br J Clin Pharmacol 11: 345?351","journal-title":"Br J Clin Pharmacol"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.0954-6820.1975.tb19578.x","volume":"198","author":"NC Henningsen","year":"1975","unstructured":"Henningsen NC, Cederberg A, Hanson A, Johansson BW (1975) Effects of long-term treatment with procaine amide. Acta Med Scand 198: 475?482","journal-title":"Acta Med Scand"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/pgmj.58.686.767","volume":"58","author":"ER Higgs","year":"1982","unstructured":"Higgs ER, Banks RA, Harrison PR, Kingswood JC, Mackenzie JC (1982) Endralazine in patients with severe hypertension and renal insufficiency. Postgrad Med J 58: 767?770","journal-title":"Postgrad Med J"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0140-6736(83)91967-0","volume":"1","author":"DG Holmes","year":"1983","unstructured":"Holmes DG, Bogers WAJL, Wideroe TE, Huunan-Seppala A, Wideroe B (1983) Endralazine, a new perpheral vasodilator: Absence of effect of acetylator status on antihypertensive effect. Lancet 1: 670?671","journal-title":"Lancet"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/art.1780240814","volume":"24","author":"GRV Hughes","year":"1981","unstructured":"Hughes GRV, Rynes RI, Gharavi A, Ryan PFJ, Sewell J, Mansilla R (1981) The heterogeneity of serologic findings and predisposing host factors in drug-induced lupus erythematosus. Arthritis Rheum 24: 1070?1073","journal-title":"Arthritis Rheum"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1055\/s-2008-1070477","volume":"106","author":"J Kindler","year":"1981","unstructured":"Kindler J, Glockner WM, Sieberth HG, Konrads A, Meurer KA, Schulz V, Vaith P (1981) Antihypertensive Wirksamkeit von Endralazin im Vergleich mit Minoxidil. Dtsch Med Wochenschr 106: 1176?1181","journal-title":"Dtsch Med Wochenschr"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/00005344-198207000-00006","volume":"4","author":"W Kirch","year":"1982","unstructured":"Kirch W, Axthelm T (1982) Endralazine, a new peripheral vasodilator ? a randomized cross-over trial against dihydralazine. J Cardiovasc Pharmacol 4: 562?566","journal-title":"J Cardiovasc Pharmacol"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1161\/01.CIR.47.6.1204","volume":"XLVII","author":"BD Kosowsky","year":"1973","unstructured":"Kosowsky BD, Taylor J, Lown B, Ritchie RF (1973) Long-term use of procaine amide following acute myocardial infarction. Circulation XLVII: 1204?1210","journal-title":"Circulation"},{"key":"CR16","first-page":"203","volume":"66","author":"HU Lehmann","year":"1977","unstructured":"Lehmann HU, Witt E, Hochrein H (1977) Hemodynamic study on a new antihypertensive drug (a pyridopyridazine) in the treatment of hypertensive crisis and resistant hypertension: first findings in man. Z Kardiol 66: 203?209","journal-title":"Z Kardiol"},{"key":"CR17","first-page":"803","volume":"120","author":"HU Lehmann","year":"1978","unstructured":"Lehmann HU, Witt E, Hochrein H (1978) Hochdruckbehandlung durch Kombination eines Pyridopyridazin-Derivats mit einem Betarezeptorenblocker. Munch Med Wochenschr 120: 803?806","journal-title":"Munch Med Wochenschr"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/bmj.284.6320.936","volume":"284","author":"R Mansilla-Tinoco","year":"1982","unstructured":"Mansilla-Tinoco R, Harland SJ, Ryan PJ, Bernstein RM, Dollery CT, Hughes GRV, Bulpitt CJ, Morgan A, Jones JM (1982) Hydralazine, antinuclear antibodies, and the lupus syndrome. Br Med J 284: 936?939","journal-title":"Br Med J"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/art.1780240816","volume":"24","author":"FC McDuffie","year":"1981","unstructured":"McDuffie FC (1981) Relationship between immune response to hydralazine and to deoxyribonucleoprotein in patients receiving hydralazine, Arthritis Rheum 24: 1079?1081","journal-title":"Arthritis Rheum"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2125.1983.tb02139.x","volume":"16","author":"PA Meredith","year":"1983","unstructured":"Meredith PA, Elliott HL, McSharry DR, Kelman AW, Reid JL (1983) The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects. Br J Clin Pharmacol 16: 27?32","journal-title":"Br J Clin Pharmacol"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/clpt.1980.234","volume":"28","author":"PA Reece","year":"1980","unstructured":"Reece PA, Cozamanis I, Zacest R (1980) Kinetics of hydralazine and its main metabolites in slow and fast acetylators. Clin Pharmacol Ther 28: 769?778","journal-title":"Clin Pharmacol Ther"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/med.2610010105","volume":"1","author":"PA Reece","year":"1981","unstructured":"Reece PA (1981) Hydralazine and related compounds: Chemistry, metabolism, and mode of action. Med Res Rev 1: 73?96","journal-title":"Med Res Rev"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0378-4347(00)80254-6","volume":"225","author":"PA Reece","year":"1981","unstructured":"Reece PA, Cozamanis I, Zacest R (1981) Sensitive high-performance liquid chromatographic assey for endralazine and two of its metabolites in human plasma. J Chromatogr 225: 151?160","journal-title":"J Chromatogr"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/BF00637500","volume":"23","author":"PA Reece","year":"1982","unstructured":"Reece PA, Cozamanis I, Zacest R (1982) Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator antihypertensive, endralazine. Eur J Clin Pharmacol 23: 523?527","journal-title":"Eur J Clin Pharmacol"},{"key":"CR25","first-page":"1843","volume":"29","author":"R Salzmann","year":"1979","unstructured":"Salzmann R, Burki H, Chu D, Clark B, Marbach P, Markstein R, Rienert H, Seigl H, Waite R (1979) Pharmakologische Wirkungen des Antihypertensivums 6-Benzoyl-3-hydrazino-5,6,7,8-tetrahydropyrido [4,3-c] pyridazin (BQ 22-708, Endralazine). Arzneimittelforsch\/Drug Res 29: 1843?1853","journal-title":"Arzneimittelforsch\/Drug Res"},{"key":"CR26","first-page":"1835","volume":"29","author":"E Schenker","year":"1979","unstructured":"Schenker E, Salzmann R (1979) Antihypertensiv wirksame bizyklische 3-Hydrazinopyridazine. Arzneimittelforsch\/Drug Res 29: 1835?1843","journal-title":"Arzneimittelforsch\/Drug Res"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1136\/bmj.284.6329.1602","volume":"284","author":"JH Silas","year":"1982","unstructured":"Silas JH, Ramsay LE, Freestone S (1982) Hydralazine once daily in hypertension. Br Med J 284: 1602?1604","journal-title":"Br Med J"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.0954-6820.1979.tb13505.x","volume":"206","author":"C Sonnhag","year":"1979","unstructured":"Sonnhag C, Karlsson E, Hed J (1979) Procainamide-induced lupus erythematosus-like syndrome in relation to acetylator phenotype and plasma levels of procainamide. Acta Med Scand 206: 245?251","journal-title":"Acta Med Scand"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/clpt.1981.46","volume":"29","author":"JA Timbrell","year":"1981","unstructured":"Timbrell JA, Harland SJ, Facchini V (1981) Effect of dose on acetylator phenotype distribution of hydralazine. Clin Pharmacol Ther 29: 337?343","journal-title":"Clin Pharmacol Ther"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/clinchem\/27.11.1911","volume":"27","author":"R Whelpton","year":"1981","unstructured":"Whelpton R, Watkins G, Curry SH (1981) Bratton-Marshall and liquid-chromatographic methods compared for determination of sulfamethazine acetylator status. Clin Chem 27: 1911?1914","journal-title":"Clin Chem"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00542414.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00542414\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00542414","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T05:39:04Z","timestamp":1585978744000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00542414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1986]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1986]]}},"alternative-id":["BF00542414"],"URL":"https:\/\/doi.org\/10.1007\/bf00542414","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[1986]]}}}